TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12563929

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fraxiparine) administered subcutaneously at 41 IU/kg.day for 3 days, then 62 IU/kg.day from day 4 to day 10.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 46
Study: 9849109

Group type: EXPERIMENTAL
Intervention: Action training
Number of subjects: 2

Group type: COMPARATOR
Intervention: Concept training
Number of subjects: 2
Study: 7912946

Group type: EXPERIMENTAL
Intervention: urapidil 0.4 mg kg‐1 i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: clonidine 2.5 micrograms kg‐1 i.v.
Number of subjects: 20
Study: 2465748

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg mixed with decaffeinated coffee)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Decaffeinated drink alone
Number of subjects: 50
Study: 29745711

Group type: EXPERIMENTAL
Intervention: Emotional segregation condition (large emotional differences between black vs. white subgroups)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (small emotional differences between black vs. white subgroups)
Number of subjects: 12
Study: 28121670

Group type: EXPERIMENTAL
Intervention: NRTI only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NNRTI-containing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protease inhibitor containing
Number of subjects: 0

Group type: COMPARATOR
Intervention: CTX use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo use
Number of subjects: 0
Study: 26192006

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Mean caffeinated coffee intake
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: rs1495741
Number of subjects: 1181
Study: 24288494

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (20 sessions, every other day, 20 minutes each session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21343579

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (15 mg/d)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 18642021

Group type: EXPERIMENTAL
Intervention: Hydrophobic AcrySof IOL (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrophilic Akreos adapt IOL (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16392026

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 4806

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 4806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4806
Study: 15164191

Group type: EXPERIMENTAL
Intervention: 600 mg slow-release valproic acid (VPA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 mg slow-release levodopa (LD) + 50 mg benserazid
Number of subjects: 20
Study: 11152791

Group type: EXPERIMENTAL
Intervention: MR imaging of alar ligaments (coronal T1‐ and T2‐weighted and transverse T1‐weighted)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MR imaging of craniocervical junction (CCJ) and C1-C2 joints
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MR imaging of C1-C2 joint
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MR imaging of CCJ and C1-C2 joints
Number of subjects: 50
Study: 9258848

Group type: EXPERIMENTAL
Intervention: Long jumpers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sprinting task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skilled jumpers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unskilled jumpers
Number of subjects: 0
Study: 8387933

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) with spacer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) with spacer
Number of subjects: 12
Study: 3311237

Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Iproplatin (360 mg/m2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cisplatin (not administered in this trial, but mentioned for comparison)
Number of subjects: 16
Study: 29178492

Group type: EXPERIMENTAL
Intervention: Coated aluminum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aluminum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ground glass diffusers
Number of subjects: 0
Study: 27031125

Group type: EXPERIMENTAL
Intervention: Presence of seropositivity
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Presence of 1 or more comorbidities including autoimmune disorders
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Thymic hyperplasia
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prognostic score classification
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Negative predictive value
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Positive predictive value
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sensitivity
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Specificity
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Area under receiver operating characteristic curve
Number of subjects: 101
Study: 25226827

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.5 g/KgBW/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isonitrogenous protein supplement (0.5 g/KgBW/day)
Number of subjects: 6
Study: 23292928

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 317
Study: 20825712

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 24 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 48 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 72 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 48 weeks in subgroup A2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 24 weeks in subgroup A1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 48 weeks in subgroup B1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 72 weeks in subgroup B2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 72 weeks in group C1
Number of subjects: 140
Study: 18094315

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (group A)
Number of subjects: 42
Study: 16398772

Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine (5 mL of 2% lignocaine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline (5 mL)
Number of subjects: 200
Study: 14657763

Group type: EXPERIMENTAL
Intervention: HIV‐1 RNA amplification assay
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PBMC microculture
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PBMC HIV‐1 DNA amplification assay
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: RNA assay
Number of subjects: 124
Study: 11019370

Group type: EXPERIMENTAL
Intervention: 5'-DFUR (600 mg/day for 2 years)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no 5'-DFUR)
Number of subjects: 62
Study: 8990730

Group type: EXPERIMENTAL
Intervention: Early intervention starting at 3 months adjusted age
Number of subjects: 65

Group type: COMPARATOR
Intervention: Delayed intervention starting at 12 months adjusted age
Number of subjects: 65
Study: 1484176

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs), specifically sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline, imipramine, and dothiepin
Number of subjects: 0
Study: 3881629

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tumorectomy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mastectomy and Tumorectomy
Number of subjects: 41
Study: 29615088

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needle release of the TCL plus corticosteroid injection (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Single ultrasound-guided needle release of the TCL (group B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 49
Study: 27179112

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 293

Group type: COMPARATOR
Intervention: No Cetuximab
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: FCGR3A (rs396991)
Number of subjects: 293
Study: 24899618

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22867978

Group type: EXPERIMENTAL
Intervention: Containers with an adapted sterilizing filter (Hyabak; Thea)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional containers
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-patient conventional containers
Number of subjects: 30
Study: 20945036

Group type: EXPERIMENTAL
Intervention: Isoflavone extract (80 mg daily for 4 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18356795

Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study: 16911252

Group type: EXPERIMENTAL
Intervention: Training (ten 5‐s contractions per day for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (contralateral untrained muscle)
Number of subjects: 29
Study: 12001756

Group type: EXPERIMENTAL
Intervention: Pregnancies with PIH
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 37
Study: 10439987

Group type: EXPERIMENTAL
Intervention: Action research intervention (facilitating practice meetings and providing written feedback)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (written feedback alone)
Number of subjects: 28
Study: 7503080

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3, 40 to 60 micrograms/d for 1 week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Postcontrol study after discontinuation of treatment
Number of subjects: 8
Study: 2240530

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg orally the night before surgery and 20 mg intramuscularly 60 minutes before induction of anaesthesia
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg orally the night before surgery and 400 mg orally 60 minutes before induction of anaesthesia
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no famotidine or cimetidine)
Number of subjects: 55
Study: 83189

Group type: EXPERIMENTAL
Intervention: Isoprinosine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31549310

Group type: EXPERIMENTAL
Intervention: Cooperative parent-mediated therapy (CPMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-intensity psychosocial intervention (LPI)
Number of subjects: 34
Study: 31172338

Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine with buccal midazolam
Number of subjects: 275
Study: 28182446

Group type: EXPERIMENTAL
Intervention: Smoking Cessation Self-Efficacy Questionnaire (SEQ-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-factor model of SEQ-12
Number of subjects: 0
Study: 25812804

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ondansetron
Number of subjects: 210

Group type: COMPARATOR
Intervention: 5 ml normal saline (Control)
Number of subjects: 210
Study: 23695174

Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Telephone delivery
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Face-to-face then telephone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Telephone then face-to-face
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: New scoring system for cognitive recovery
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Assessment at 3 days
Number of subjects: 143
Study: 21384066

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist team management
Number of subjects: 253

Group type: COMPARATOR
Intervention: Physician(s) only management
Number of subjects: 253
Study: 19602104

Group type: EXPERIMENTAL
Intervention: Mini-screw implants (G1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transpalatal arches (G2)
Number of subjects: 34
Study: 17028992

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral stress management expressive supportive therapy (CBSM+) intervention plus a healthier lifestyles (HL) component
Number of subjects: 237

Group type: COMPARATOR
Intervention: Individual educational/informational format plus HL
Number of subjects: 237
Study: 10632913

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.2 mg.kg‐1 up to 5 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 71
Study: 9162432

Group type: EXPERIMENTAL
Intervention: Low dose insulin (physiological concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose insulin (physiological concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no insulin)
Number of subjects: 0
Study: 1519121

Group type: EXPERIMENTAL
Intervention: Granuflex‐E (occlusive dressing)
Number of subjects: 10

Group type: COMPARATOR
Intervention: tulle gras (semi‐open dressing)
Number of subjects: 10
Study: 6523326

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (500 mg three times daily for 7-14 days)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Doxycycline (100 mg three times daily for 7-14 days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (in culture-negative group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Doxycycline (in culture-negative group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 122
Study: 30531832

Group type: EXPERIMENTAL
Intervention: Veliparib (200 mg BID for 7 days of each 14‐day cycle) + FOLFIRI
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo + FOLFIRI
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Veliparib + FOLFIRI
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 29535060

Group type: EXPERIMENTAL
Intervention: 22-gauge needle with suction
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 22-gauge needle without suction
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 25-gauge needle with suction
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: 25-gauge needle without suction
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: ROSE
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Cell block
Number of subjects: 352
Study: 26694545

Group type: EXPERIMENTAL
Intervention: GLP‐1 receptor antagonist exendin‐(9‐39)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 500 pmol/kg/min of exendin‐(9‐39)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 pmol/kg/min of exendin‐(9‐39)
Number of subjects: 6
Study: 24152055

Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Combined PDA and CDSMP
Number of subjects: 376

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 376
Study: 22456303

Group type: EXPERIMENTAL
Intervention: Oral solution of lesogaberan (100 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Modified release (MR) capsules of lesogaberan (50% dissolution over 4 h)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Modified release (MR) capsules of lesogaberan (100% dissolution over 4 h)
Number of subjects: 57
Study: 20152871

Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min running at 68.8% of maximum oxygen uptake)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min running)
Number of subjects: 9
Study: 16860976

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) preparation (2 g/meal=6 g/day) for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16009907

Group type: EXPERIMENTAL
Intervention: High-dose interferon beta 1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS relapses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable patients
Number of subjects: 0
Study: 11850287

Group type: EXPERIMENTAL
Intervention: GW 420867X 50 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: GW 420867X 100 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: GW 420867X 200 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1000
Study: 10420495

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 40 mg or 60 mg per day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fluoxetine (FLX) 20 mg per day
Number of subjects: 53
Study: 7674813

Group type: EXPERIMENTAL
Intervention: Besipirdine hydrochloride (10, 20, 30, 40 mg bid for 2 days each, followed by 50 and 60 mg bid for 5 days each)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2189040

Group type: EXPERIMENTAL
Intervention: 2 cans/day of mackerel fillet in tomato pulp for 2 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3 cans/week of mackerel for 8 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: 2 cans/day of herring fillet in tomato pulp for 2 weeks
Number of subjects: 44
Study: 31404539

Group type: EXPERIMENTAL
Intervention: Whole chocolate bar (100g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Segmented chocolate pieces (6 pieces)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High chocolate specific appetite
Number of subjects: 80
Study: 30242380

Group type: EXPERIMENTAL
Intervention: Use of medical scribes during clinic visits
Number of subjects: 18
Study: 26809247

Group type: EXPERIMENTAL
Intervention: Temporary fracture fixation with external fixation and defined secondary definitive treatment (DCO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Primary reamed nailing (early total care)
Number of subjects: 34
Study: 23461895

Group type: EXPERIMENTAL
Intervention: BMS-936557 (10 mg/kg) intravenously every other week
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: BMS-936557 (Cminss 108-235 μg/ml)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: BMS-936557
Number of subjects: 109
Study: 22100823

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 μg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 μg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 μg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 0 μg
Number of subjects: 40
Study: 20236906

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diode laser (980 nm) with scaling and root planing (SRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nd:YAG laser (1,064 nm) with scaling and root planing (SRP)
Number of subjects: 0
Study: 18036359

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 159

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 159
Study: 16131708

Group type: EXPERIMENTAL
Intervention: Men (isometric muscle actions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Women (isometric muscle actions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Men (MMG mean power frequency vs. isometric torque)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Women (MMG mean power frequency vs. isometric torque)
Number of subjects: 15
Study: 12040649

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology of fibroadenoma with multinucleated stromal giant cells
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Histologic examination of lumpectomy specimens
Number of subjects: 2
Study: 10524660

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg/min for 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (14 healthy subjects)
Number of subjects: 12
Study: 7675964

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10
Study: 2076408

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine + Chlorthalidone
Number of subjects: 0
Study: 6766733

Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adenine arabinoside (ara‐A)
Number of subjects: 0
Study: 31830835

Group type: EXPERIMENTAL
Intervention: Peri-conceptional progesterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29741688

Group type: EXPERIMENTAL
Intervention: Exercise education and motivational interview program based on the stages of change model (SCM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 28802289

Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only (control)
Number of subjects: 60
Study: 25679364

Group type: EXPERIMENTAL
Intervention: Computerized screening and motivational intervention (ASSIST/MBIc)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Non-computerized screening and motivational intervention (ASSIST/MBIi)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Screening only (control)
Number of subjects: 458